Kaleido Biosciences (KLDO) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock KLDO vs. ELYS, GROM, KBNT, ALFIW, APCXW, ARBEW, AOGOW, AOGOU, AUROW, and AVPTWShould you be buying Kaleido Biosciences stock or one of its competitors? The main competitors of Kaleido Biosciences include Elys BMG Group (ELYS), Grom Social Enterprises (GROM), Kubient (KBNT), Alfi (ALFIW), AppTech Payments (APCXW), Arbe Robotics (ARBEW), Arogo Capital Acquisition (AOGOW), Arogo Capital Acquisition (AOGOU), Aurora Innovation (AUROW), and AvePoint (AVPTW). These companies are all part of the "computer software" industry. Kaleido Biosciences vs. Its Competitors Elys BMG Group Grom Social Enterprises Kubient Alfi AppTech Payments Arbe Robotics Arogo Capital Acquisition Arogo Capital Acquisition Aurora Innovation AvePoint Kaleido Biosciences (NASDAQ:KLDO) and Elys BMG Group (NASDAQ:ELYS) are both small-cap computer software companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Does the media prefer KLDO or ELYS? In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled Elys BMG Group'saverage media sentiment score. Company Overall Sentiment Kaleido Biosciences Neutral Elys BMG Group Neutral Is KLDO or ELYS more profitable? Company Net Margins Return on Equity Return on Assets Kaleido BiosciencesN/A N/A N/A Elys BMG Group N/A N/A N/A Do insiders and institutionals hold more shares of KLDO or ELYS? 81.6% of Kaleido Biosciences shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by company insiders. Comparatively, 18.5% of Elys BMG Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, KLDO or ELYS? Kaleido Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Elys BMG Group has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Which has better earnings and valuation, KLDO or ELYS? Elys BMG Group has higher revenue and earnings than Kaleido Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/AElys BMG Group$43.86M0.00-$18.26MN/AN/A SummaryElys BMG Group beats Kaleido Biosciences on 4 of the 5 factors compared between the two stocks. Get Kaleido Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLDO vs. The Competition Export to ExcelMetricKaleido BiosciencesBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.39M$138.42M$5.70B$9.81BDividend YieldN/A3.74%4.61%4.07%P/E Ratio0.003.8230.6225.55Price / SalesN/A4,352.71465.58116.50Price / CashN/A13.1938.2159.48Price / BookN/A45.639.026.15Net Income-$95.48M-$90.99M$3.25B$264.98M Kaleido Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLDOKaleido BiosciencesN/AN/AN/AN/A$6.39M$1.10M0.0080ELYSElys BMG GroupN/A$0.00-75.0%N/AN/A$16K$43.86M0.0090Gap UpHigh Trading VolumeGROMGrom Social Enterprises0.2005 of 5 stars$0.00flatN/A-99.8%$4K$3.72M0.00450KBNTKubientN/AN/AN/AN/A$1K$1.17M0.0040Gap UpALFIWAlfiN/AN/AN/AN/A$0.00$200.68K0.0040APCXWAppTech PaymentsN/A$0.15flatN/A-56.3%$0.00$276K0.0020ARBEWArbe RoboticsN/A$0.23-2.6%N/A-22.8%$0.00$671K0.00120Gap DownAOGOWArogo Capital AcquisitionN/A$0.03flatN/AN/A$0.00N/A0.00N/AAOGOUArogo Capital AcquisitionN/A$8.50flatN/AN/A$0.00N/A0.00N/AAUROWAurora InnovationN/A$0.82+0.9%N/A+248.0%$0.00$1M0.001,700AVPTWAvePointN/A$5.99-9.9%N/A+254.7%$0.00$349.01M0.001,930Gap Down Related Companies and Tools Related Companies Elys BMG Group Competitors Grom Social Enterprises Competitors Kubient Competitors Alfi Competitors AppTech Payments Competitors Arbe Robotics Competitors Arogo Capital Acquisition Competitors Arogo Capital Acquisition Competitors Aurora Innovation Competitors AvePoint Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLDO) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kaleido Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access